Pfizer offer for remaining shares "undervalues Icagen's assets"
This article was originally published in Scrip
Executive Summary
Merlin Nexus, Icagen's biggest shareholder after Pfizer, and New Leaf Venture Partners have lashed out against Pfizer for its recent move to acquire the remaining stake in partner Icagen that it already does not own for $6 per share, which would value the biotech at about $56 million.